New perspectives of Hyaluronic Acid in the upper airway chronic inflammation diseases

Casale, Manuele*
Department of Otolaryngology, University Campus Bio-Medico, Italy

Submission: December 02, 2015; Published: December 22, 2015

*Corresponding author: Casale, Manuele, Department of Otolaryngology, Unit of Otolaryngology, University Campus Bio-Medico, Rome, Italy.

Editorial

Hyaluronic acid (HA) is a naturally occurring polysaccharide which consists of a linear chain of fragments of d-glucuronic acid and N-acetyl-glucosamine linked by alternating β-3 and-β4 bonds.

It is an abundant constituent of the extracellular matrix of connective tissue, synovial fluid, embryonic mesenchyme, vitreous humor, skin, and several other organs and tissues of the human body [1].

HA plays a pivotal role in the homeostasis of respiratory apparatus.

High molecular weight HA is broken down under the influence of free radicals and enzymes during inflammation. Low molecular weight fragments deliver signal about tissue damage and mobilize immune cells, while high molecular weight form suppresses immune response preventing from excessive exacerbations of inflammation [2,3].

HA, which is a hygroscopic macromolecule and its solutions are highly osmotic, forms a scaffold that several sulfur proteoglycans bind to. Such structures can reach large size and are able to trap large quantities of water and ions, providing hydration and tissue turgescence.

In the upper airway HA is primarily involved in the regulation of vasomotor tone and gland secretion and it significantly contributes to nasal mucosal host defense, stimulating ciliary clearance. Up to date, HA is widely used in several other branches of medicine and neither contraindications nor interactions with drugs are reported [4-6].

Some studies showed a role of HA in patients with upper aero-digestive tract (UAD'T) chronic inflammatory disease [7], first of all in patients affected by chronic rhinosinusitis (CRS).

CRS is one of the most common chronic diseases in the United States affecting an estimated 35 million people and is one of the most common causes of absence from work and for visits to a family doctor’s office. HA could be a new CRS treatment strategy that can minimize symptoms, promote recovery and prevent exacerbations [8,9].

In the same time, despite many advances in functional endoscopic nasal and sinus surgery, in the first weeks after procedures painless lavages of nasal fossae provide to eliminate secretions, crusts, and debris, procedure necessary to achieve complete recovery. Several different solutions are usually used for nasal lavages such as isotonic, hypertonic, or alkaline-buffered saline as well as ocean water have been used for nasal lavage. Topical HA administration could represent a supportive treatment for faster improvement of nasal respiration, also minimizing patients’ discomfort in postoperative nasal and sinus surgery, promoting nasal mucosa healing in the first weeks after procedure [10-14].

Last but not least, some studies showed that topical HA can be an useful tool also in children affected by recurrent upper respiratory tract infections and to relief respiratory symptoms in cystic fibrosis [15,16].

To date, topical therapies guarantee a better delivery of high concentrations of pharmacologic agents to the nasal mucosa.

The strong connection between particle diameter and site of the high concentration of nebulized particles in the upper airway suggests that it should be mandatory to carefully choose the nebulizer device to get better therapeutic results.

Further studies on larger populations and with new specific nebulization devices for upper airway are needed to confirm these encouraging results on HA in chronic upper airway inflammation disease.
References

1. Ialenti A, Di Rosa M (1994) Hyaluronic acid modulates acute and chronic inflammation. Agents Actions 43(1-2): 44-47.

2. Manzanares D, Monzon ME, Savani RC, Salathe M (2007) Apical oxidative hyaluronan degradation stimulates airway ciliary beating via RHAMM and RON. Am J Respir Cell Mol Biol 37(2): 160-168.

3. Wolny PM, Banerji S, Gounou C, Brisson AR, Day AJ, et al. (2010) Analysis of CD44-hyaluronan interactions in an artificial membrane system: insights into the distinct binding properties of high and low molecular weight hyaluronan. Biol Chem 285(39): 30170-30180.

4. Jentsch H, Ponomovski R, Kandt G, Goke R (2003) Treatment of gingivitis with hyaluronic. J Clin Periodontol 30(2): 159-164.

5. Rodriguez-Merchan EC (2013) Intra-articular Injections of Hyaluronic Acid and Other Drugs in the Knee Joint. HSS J 9(2): 180-182.

6. Migliore A, Granata M (2008) Intra articular use of hyaluronic acid in the treatment of osteoarthritis. Clin Interv Aging 3(2): 365-369.

7. Casale M, Moffa A, Sabattino L, Pace A, Oliveto G, et al. (2015) Hyaluronic Acid: Perspectives in Upper Aero-Digestive Tract. A Systematic Review. PLoS One 10(6): e0130637.

8. Casale M, Sabatino L, Frani V, Mazzola F, Dell’ Aquila R, et al. (2014) The potential role of hyaluronan in minimizing symptoms and preventing exacerbations of chronic rhinosinusitis. Am J Rhinol Allergy 28(4): 345-348.

9. Cassandro E, Chiarella G, Cavaliere M, Sequino G, Cassandro C, et al. (2014) Hyaluronic Acid in the Treatment of Chronic Rhinosinusitis with Nasal Polyposis. Indian J Otolaryngol Head Neck Surg 67(3): 299-307.

10. Macchi A, Terranova P, Deggio E, Castelnuovo P (2013) Hyaluronan plus saline nasal washes in the treatment of rhino-sinusal symptoms in patients undergoing functional endoscopic sinus surgery for rhino-sinusal remodeling. Int J Immunopathol Pharmacol 26(1): 137-145.

11. Gelardi M, Guglielmi AV, De Candia N, Maffeioni E, Berardi P, et al. (2013) Effect of sodium hyaluronate on mucociliary clearance after functional endoscopic sinus surgery. Eur Ann Allergy Clin Immunol 45(3): 103-108.

12. Cantone E, Castagna G, Scagnano S, Ferranti I, Rega F, et al. (2014) Impact of intranasal sodium hyaluronate on the short-term quality of life of patients undergoing functional endoscopic sinus surgery for chronic rhinosinusitis. Int Forum Allergy Rhinol 4(6): 484-487.

13. Goutova I, Shah-Hosseini K, Meiser P (2014) Clinical efficacy of a spray containing hyaluronic Acid and dexamethasone after surgery in the nasal cavity (septoplasty, simple ethmoid sinus surgery, and turbinate surgery). J Allergy (Cairo) 635490.

14. Lam K, Tan BK, Lavin JM, Meen E, Conley DB (2013) Comparison of nasal sprays and irrigations in the delivery of topical agents to the olfactory mucosa. Laryngoscope 123(12): 2950-2957.

15. Ros M, Casciaro R, Lucca F, Troiani P, Saloniini E, et al. (2013) Hyaluronic Acid Improves the Tolerability of Hypertonic Saline in the Chronic Treatment of Cystic Fibrosis Patients: A Multicenter, Randomized, Controlled Clinical Trial. J Aerosol Med Pulm Drug Deliv 27(2): 133-137.

16. Macchi A, Castelnuovo P, Terranova P, Deggio E (2013) Effects of sodium hyaluronate in children with recurrent upper respiratory tract infections: results of a randomised controlled study. Int J Immunopathol Pharmacol 26(1): 127-135.